HSV keratitis treatment recommendations take trial evidence, clinical experience into account

Article

Evidence-based medicine has provided some guidance on the management of herpes simplex virus (HSV) keratitis, but there are still many questions left unanswered, said Thomas J. Liesegang, MD, at the World Congress of Ophthalmology.

Evidence-based medicine has provided some guidance on the management of herpes simplex virus (HSV) keratitis, but there are still many questions left unanswered, said Thomas J. Liesegang, MD, at the World Congress of Ophthalmology.

Based on the findings from The Herpetic Eye Disease Study (HEDS) project and his own experience, Dr. Liesegang offered some suggestions to the audience at a session highlighting a potpourri of clinical pearls from American Academy of Ophthalmology board members.

For epithelial HSV keratitis, topical antiviral treatment is appropriate whereas oral acyclovir (Zovirax) started during acute dendritic or geographic keratitis does not prevent stromal disease. Once there is disciform or necrotizing stromal HSV keratitis, topical steroids should be used as they have been shown to hasten resolution without causing recurrent herpetic keratitis.

"In one HEDS trial, oral acyclovir was found ineffective for treating non-necrotizing stromal keratitis. However, there is a strong rationale for its use in necrotizing keratitis," said Dr. Liesegang, professor of ophthalmology, Mayo Clinic, Jacksonville, FL.

For eyes with iridocyclitis, limited data from a prematurely terminated HEDS study showed oral acyclovir may be effective, and Dr. Liesegang noted he prescribes a topical steroid in that situation. In another HEDS trial, oral acyclovir 400 mg BID given for 1 year after the onset of active HSV was demonstrated to decrease the recurrence of epithelial and stromal HSV keratitis.

Dr. Liesegang noted that antiviral treatment in the HEDS studies was limited to oral acyclovir and topical trifluridine (Viroptic).

"Now, other antiviral agents with better bioavailability are available and they may be effective. However, we still have no agents that are effective against latent HSV and there is no indication that a vaccine will be immediately available," he said.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.